Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
REGULATORY
Pharma Industry Might Accept Comparator PMP Deduction If No Eligible Use Added in 6 Years
The pharmaceutical industry strongly opposes a simple expansion of the current rule to deduct the price maintenance premium (PMP) from PMP-granted comparator drugs in the pricing of new medicines deemed PMP-ineligible, but might accept such deduction if no PMP-eligible indications…
To read the full story
Related Article
- “Third Price Revision” Eyed for Expansion of Comparator PMP Deduction Rule
December 11, 2019
- Chuikyo Pushes Up-to-5-Band Plan to Address Unreasonable Generic Price Rises, Prods Industry Reorganization
December 9, 2019
- US, European Trade Groups Oppose Tighter Re-Pricing Rules
December 9, 2019
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
REGULATORY
- Pharma in Dogged Fight against Expansion of CEA Price Tweaks, Flags “Camel’s Nose”
November 29, 2023
- Japan Ambassador Meets Astellas Employee Detained in China
November 29, 2023
- Japan Approves Meiji’s COVID Vaccine, Daiichi Sankyo’s XBB-Tailored Jab
November 28, 2023
- Syphilis Cases in Japan Mark Record High for 3rd Consecutive Year
November 28, 2023
- LDP League Leader Vows to Push Self-Medication to Sustain Healthcare System
November 28, 2023
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…